Dr Katie Kelley talks to ecancer in an online interview for the ASCO virtual meeting 2020 about using durvalumab and tremelimumab for the treatment of advanced hepatocellular carcinoma.
She initially gives a thorough description of the trial design and rationale for the four study arms.
Dr Kelley proceeds to detail the results and whether the endpoints were met, and also some interesting outcomes from the biomarker analyses.
She looks forward to new data coming out, including the HIMALAYA trial.